Immuneering/$IMRX
13:30
09:10
04:45
00:25
20:00
1D1W1MYTD1Y5YMAX
About Immuneering
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.
Ticker
$IMRX
Sector
Primary listing
Employees
54
Headquarters
Website
Immuneering Metrics
BasicAdvanced
$356M
-
-$1.88
0.37
-
Price and volume
Market cap
$356M
Beta
0.37
52-week high
$10.08
52-week low
$1.10
Average daily volume
2.8M
Financial strength
Current ratio
3.703
Quick ratio
3.52
Long term debt to equity
12.557
Total debt to equity
13.826
Profitability
EBITDA (TTM)
-63.7
Management effectiveness
Return on assets (TTM)
-68.37%
Return on equity (TTM)
-130.47%
Valuation
Price to book
7
Price to tangible book (TTM)
9.25
Price to free cash flow (TTM)
-3.617
Free cash flow yield (TTM)
-27.65%
Free cash flow per share (TTM)
-1.557
Growth
Earnings per share change (TTM)
-1.60%
3-year earnings per share growth (CAGR)
1.43%
What the Analysts think about Immuneering
Analyst ratings (Buy, Hold, Sell) for Immuneering stock.
Bulls say / Bears say
Phase 2a results showed 94% overall survival and 72% progression-free survival at 6 months for atebimetinib + mGnP as first-line treatment for pancreatic cancer (N=34), with median OS and PFS not yet reached, indicating best-in-class tolerability and efficacy (GlobeNewswire)
At the 9-month follow-up, overall survival was 86% and progression-free survival was 53%, maintaining a strong advantage over standard care and supporting plans for a pivotal trial by end of 2025 (GlobeNewswire)
The U.S. Patent and Trademark Office granted a composition of matter patent for atebimetinib on July 9, 2025, extending exclusivity through 2042 and enhancing long-term intellectual property protection (GlobeNewswire)
Cash and cash equivalents stood at $26.4 million as of June 30, 2025, and with a quarterly cash burn of approximately $9.5 million, funding is only sufficient into 2026, requiring additional capital to complete pivotal trials (GlobeNewswire)
The underwritten public offering on September 25, 2025 issued 18,959,914 new shares at $9.23 each, diluting existing shareholders and potentially pressuring the stock price (GlobeNewswire)
With no product revenue and a net loss of $14.4 million in Q2 2025, the company remains unprofitable and continues to rely on external financing rather than commercial sales (GlobeNewswire)
Data summarised monthly by Lightyear AI. Last updated on 23 Oct 2025.
Immuneering Financial Performance
Revenues and expenses
Immuneering Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Immuneering stock?
Immuneering (IMRX) has a market cap of $356M as of October 24, 2025.
What is the P/E ratio for Immuneering stock?
The price to earnings (P/E) ratio for Immuneering (IMRX) stock is 0 as of October 24, 2025.
Does Immuneering stock pay dividends?
No, Immuneering (IMRX) stock does not pay dividends to its shareholders as of October 24, 2025.
When is the next Immuneering dividend payment date?
Immuneering (IMRX) stock does not pay dividends to its shareholders.
What is the beta indicator for Immuneering?
Immuneering (IMRX) has a beta rating of 0.37. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.